Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP187 vs Fumaderm in Moderate to Severe Plaque Psoriasis
NCT01815723Phase 3Withdrawn
- Sponsor
- Forward Pharma
- Start
- Jun 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of FP187-V2B in plaque psoriasis, sponsored by Forward Pharma. Planned start Jun 2016; status: withdrawn.
02
Drugs
FP187-V2B
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01815723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01815723.